Klotz L et al. - Most of these trials have evaluated flutamide or nilutamide. Several meta-analyses suggest a modest survival benefit of these drugs, amounting to an 8% mortality reduction at 5 years. Preclinical data and two randomized trials – one historic and one current – suggest that bicalutamide may be a more effective drug in this respect.
See all
